To determine the clinical relevance of in vitro drug chemoresistance in childhood acute myeloid leukemia, we used an MTT assay to test leukemic cells from 132 newly diagnosed children. Patients were diagnosed according to the French-AmericanBritish (FAB) classification as follows: M0 (n = 12), M1 (n = 16), M2 (n = 53), M4 (n = 17), M5 (n = 19) and M7 (n = 15). The results revealed that, compared to leukemic cells from completeresponders (n = 107), those from non-responders who failed induction therapy (n = 17) were 1.4 to 5.0 times more resistant in vitro to cytarabine (P = 0.005), melphalan (P = 0.003), etoposide (P = 0.011), L-asparaginase (P = 0.017), aclarubicin (P = 0.026) and dexamethasone (P = 0.039). For seven other drugs tested, the median lethal dose of 70% and leukemic cell survival of non-responders were higher than those of complete-responders, but the difference was not statistically significant. We sought correlations between FAB subtypes and in vitro drug resistance. Leukemias of the FAB M4 and M5 subtype were more sensitive to L-asparaginase (P = 0.01, P = 0.0036) than those of the FAB M2 subtype. FAB M5 leukemia was more sensitive to etoposide than were the FAB M2, M4 and M7 subtypes (P = 0.001, P = 0.034, P = 0.023, respectively). By contrast, FAB M5 leukemia was significantly more resistant to prednisolone and dexamethasone than were the FAB M0, M1, M2, M4 and M7 subtypes. We sought correlations between in vitro drug resistance and long-term clinical outcome, but found no associations in this case. These results suggest that in vitro resistance to cytarabine, melphalan, etoposide, L-asparaginase, aclarubicin and dexamethasone might represent factors that can predict response to the early course of therapy. Selecting an appropriate anti-cancer drug according to the FAB classification together with drug sensitivity testing may contribute to improved prognoses in childhood acute myeloid leukemia. Leukemia (2001Leukemia ( ) 15, 1892Leukemia ( -1897 
Introduction
Advances in intensive chemotherapy have led to improved outcome for children with acute myeloid leukemia (AML). Approximately 70-90% of childhood AML patients can achieve remission and about 30-50% of childhood AML patients remain in continuous remission at 5 years. [1] [2] [3] [4] Recently, a complete remission rate of about 90% has been achieved in Japan. 5 Drug sensitivity testing may be able to provide clinically valuable information. Cellular drug resistance is related to poor prognosis in childhood acute lymphoblastic leukemia. [6] [7] [8] [9] [10] [11] There are some reports on AML using the MTT (methyl-thiazoltetrazolium) assay, [12] [13] [14] [15] [16] [17] but thus far we have found only a limited number of studies on the relationship between in vitro drug resistance and clinical outcomes in childhood AML. 6, [14] [15] [16] [17] Here, we have investigated in vitro drug resistance using the MTT assay for 132 patients with newly diagnosed AML. We show Initially, 159 patients (aged 0-16 years) with AML, diagnosed between January 1988 and February 2000, were eligible for this study. Seven patients were excluded because tests showed less than 70% of bone marrow (BM) blasts in three samples and a lack of cells in four samples. Twelve patients with French-American-British (FAB) M7 with Down's syndrome, and seven patients with M3 were excluded because of their biological specificity, and one patient with M6 was excluded because of the small number for statistical analysis. The diagnosis of AML was based on cytomorphology and cytochemistry performed at the individual institutions. [18] [19] [20] BM or peripheral blood (PB) samples that included more than 70% leukemic cells were collected from the 132 patients. The mononuclear cells were separated by density gradient centrifugation using Ficoll-Paque (Pharmacia, Uppsala, Sweden) at 400 g for 20 min at room temperature. After separation, the mononuclear cells were washed twice in RPMI 1640 medium, and in vitro testing was carried out. For testing, we prepared a culture medium of 10% fetal calf serum and RPMI 1640 medium supplemented with insulin, transferrin, and sodium selenite. All tests were started within 24 h of sampling. We obtained informed consent from all patients or their parents before sampling.
Most patients were treated according to the ANLL 91 or the CCLSG protocol. Remission induction therapy for AML in the ANLL 91 protocol consists of a combination of mitoxantrone (MIT), etoposide (VP16) and cytarabine (AraC) as follows: VP16 150 mg/m 2 /day 2 h days 1-5; AraC 200 mg/m 2 /day 12 h days 6-12; MIT 5 mg/m 2 /day 2 h days 6-10. Remission induction therapy in the CCLSG protocol consists of a combination of pirarubicin (THP), vincristine (VCR) and AraC. Complete remission (CR) was defined as a normocellular BM containing less than 5% blasts and no manifestation of leukemia elsewhere. Non-response (NR) was defined as more than 25% residual leukemic cells in BM, and partial remission (PR) was defined as 5-25% remaining leukemic cells in BM after induction therapy.
All data regarding sex, age at onset, initial white blood cell (WBC) count, FAB classification, chromosomal analysis, treatment protocols, clinical response and clinical events were obtained from participating institutions within 2 months of diagnosis and once a year thereafter. To relate the latest data to clinical outcome, we re-evaluated on 1 August 2000.
In vitro drug resistance
In vitro drug sensitivity was measured by the MTT assay. To summarize the test principles, 2 × 10 5 cells/well were cultured in 96-well plates (Nunc, Roskilde, Denmark) in the absence (control) or presence of five concentrations of each drug for 4 days. Thirteen drugs at the following maximum concentrations (g/ml) were used: daunorubicin (DNR, 1.0 g/ml), aclarubicin (ACR, 1.0 g/ml), etoposide (VP16, 20 g/ml), lasparaginase (L-ASP, 10 IU/ml), pirarubicin (THP, 1.0 g/ml), mitoxantrone (MIT, 0.4 g/ml), melphalan (L-PAM, 80 g/ml), 4-hydroperoxy-cyclophosphamide (4-HC, 40 g/ml), cytarabine (AraC, 40 g/ml), vincristine (VCR, 1.0 g/ml), vinblastine (VLB, 10 g/ml), prednisolone (Pred, 100 g/ml) and dexamethasone (Dex, 4.0 g/ml).
The highest dose of each drug used was calculated from the maximal serum concentration achieved by standard-or highdose clinical treatment. After incubation of cells in a 5% carbon dioxide atmosphere at 37°C, the supernatant was aspirated. We then added 10 l of a 5 mg/ml solution of MTT dye (Sigma, St Louis, MO, USA) to each well. The plates were incubated for another 6 h. The tetrazolium salt was reduced to a colored formazan by living cells but not by dead cells. The formazan crystals were dissolved with 100 l acidified propanol. The optical density (OD) was measured at 540 nm (reference wave at 630 nm) using a microplate reader. If the OD in the control wells was less than 0.050, results were not evaluated due to unreliability. We did not determine the day 4 blast percentage in the control wells, and this means that, although the samples were filled with most leukemic cells at initial onset, for a minority of the samples the assay results may not be representative for the leukemic cells. We calculated the 70% lethal dose in vitro (LD70) from the doseresponse curve for 11 drugs, but for Dex and Pred, results were expressed as percentage of leukemic cell survival (LCS), because these agents failed to yield a dose-response cytotoxicity curve within the tested range. We calculated the LCS as follows: LCS (%) = (OD drug exposed well/mean OD drugfree wells) × 100. The LCS (%) for each sample was the mean percentage calculated from the LCSs of five concentrations.
Statistical analysis
All data were analyzed using StatView-J4.5 and Survival Tools (Abacus Concepts, Berkeley, CA, USA) for Macintosh. We used the Kaplan-Meier method to estimate survival curves. Event-free survival (EFS) is defined as the time from diagnosis to the occurrence of a leukemic event, ie the first relapse or disease-related death. Non-responders are classified by an 'event' occurring on day 1. Bone marrow transplantation (BMT) was not censored. Probabilities of event-free survival were tested for significance using the log-rank test. We compared the clinical and laboratory data using the Mann-Whitney U test and contingency table analysis (Fisher's exact test). A P value of less than 0.05 was considered statistically significant.
Results

Patients' characteristics and clinical outcomes
The in vitro drug sensitivity test was evaluated in 132 patients: 64 boys and 68 girls, median age 7.0 years (range 1 months to 16 years). The patients' characteristics are shown in Table 1 . The median WBC count of the patients was 13.5 × 10 9 /l (1.0-1401.6 × 10 9 /l). Table 1 ). The 4-year EFS for boys was better than that for girls (P = 0.031). We found no relationship between the 4-year EFS and clinical features such as age (P = 0.225), WBC count (P = 0.264) and FAB subtype (P = 0.209). We found no relationship between sex and age, and in vitro sensitivity to any tested drug. The clinical response to induction chemotherapy was also evaluated in all patients. We investigated the relationship between responses to induction therapy and in vitro chemosensitivity. On induction therapy, 107 patients entered CR, and eight patients achieved PR. Seventeen patients failed to achieve CR or PR (non-responders). Non-responders in each FAB subtype were as follows: M0 (n = 3), M1 (n = 1), M2 (n = 6), M4 (n = 1), M5 (n = 3) and M7 (n = 3). The frequency of non-responders in M0 (25%) was higher than in M1 (6.3%), M2 (11%), M4 (5.9%), M5 (15.8%) and M7 (20%).
Relationship of in vitro drug resistance and clinical response
The mean OD in the control wells (±s.d.; standard deviation) per 10 5 viable cells was 0.366 (±0.257). The mean OD according to FAB subtype was 0.206 (±0.166) for M0, 0.334 (±0.215) for M1, 0.366 (±0.238) for M2, 0.555 (±M0.364) for M4, 0.417 (±0.218) for M5 and 0.250 (±0.198) for M7. The mean OD for M4 was significantly higher than for M0 (P = 0.0002), M1 (P = 0.01), M2 (P = 0.006) and M7 (P = 0.0006).
To examine the in vitro drug resistance of leukemic cells from non-responders, we compared the LD70 or LCS for each drug between 107 complete-responders and 17 nonresponders. We found that in vitro drug resistance to six drugs, AraC, L-PAM, VP16, L-ASP, ACR, and Dex, was associated with the response to induction therapy (Table 2 and Figure 1 ). The median LD70 (g/ml) for L-PAM was 80 (3. Correlation between clinical response to induction therapy and in vitro drug resistance. Median LD70 of non-responders (NR) was significantly higher than that of complete-responders (CR) for anticancer drugs (AraC, VP16).
(0.34-10) in non-responders vs 4.8 (0.002-10) in completeresponders. The non-responder group was significantly resistant to L-PAM (P = 0.003), to AraC (P = 0.005), to VP16 (P = 0.011), to L-ASP (P = 0.017), to ACR (P = 0.026) and to Dex (P = 0.039), compared to the complete-responder group. The resistance ratio (RR), calculated as the ratio of the LD70 (or LCS) of non-responders to that of complete-responders, was 1.4 for Dex, 2.1 for L-ASP, 2.7 for ACR, 2.9 for VP16, 3.1 for L-PAM and 5.0 for AraC. For the other seven drugs, the median LD70 or LCS of non-responders tended to be higher than that of complete-responders, but the difference was not statistically significant.
Next, we compared the median LD70 or LCS for each drug between 107 complete-responders and eight partialresponders. However, we could not find a significant difference between these two groups. We also compared the median LD70 or LCS for each drug between 17 nonresponders and eight partial-responders. The median LD70 or LCS in non-responders was higher than in partial-responders for all drugs. Specifically, the median LD70 (g/ml) for AraC was 6.0 (0.09-40) in non-responders vs 0.47 (0.064-3.4) in partial-responders (P = 0.0026), while that for L-PAM was 80 (3.2-80) in non-responders vs 15 (6.2-24) in partialresponders (P = 0.016). We also sought the correlation between in vitro drug resistance and long-term clinical outcome, but found no statistical correlation between them.
Drug resistance with regard to the FAB classification
We compared the in vitro drug resistance of leukemias with different FAB classification. For L-ASP, M1, M4 and M5 cells were significantly more sensitive than M2 cells (Table 3 and Figure 2 ). For L-ASP, the resistance ratio (RR), calculated as the ratio of LD70 of M2 to that of M1, was 62.5. Interestingly, M1 cells were also more significantly sensitive than M4 (P = 0.01) and M5 (P = 0.023) cells. For VP16, M5 cells were significantly more sensitive than M2, M4 and M7 cells (P = 0.001, P = 0.034, P = 0.023, respectively). For VP16, the RR, calculated as the ratio of LD70 of M2 to that of M5, was 3.6. By contrast, M5 cells were significantly more resistant to Pred and Dex than were M0, M1, M2, M4 and M7 cells (from P Ͻ 0.0001 to P = 0.023, respectively, Figure 2 ). For ACR, M4 cells were significantly more sensitive than M5 cells (P = 0.023). For THP and MIT, M1 cells were more significantly sensitive than M2 and M7 cells. For the other anthracyclines (DNR and ACR), the median LD70 for M1 cells was lower than for M2 and M7 cells, but the differences did not reach significance. Excluding the anthracyclines, M1 cells were more significantly sensitive to VP16, L-ASP and L-PAM than were M2 cells (P = 0.017, P Ͻ 0.0001, P = 0.026, respectively). For AraC, M0 cells were more resistant than any other FAB subtypes, and the difference between M0 and M4 was significant (P = 0.016).
Discussion
Combination chemotherapy and supportive care has had a beneficial effect on clinical outcome in childhood AML. Currently, about 80% patients of newly diagnosed AML patients achieve complete remission and this results in about 50% 5-year survival. [1] [2] [3] The MRC AML trial has reported a complete remission rate of 92%, and a 7-year EFS of 48%. 4 Kigasawa 5 recently reported that about 90% of children with AML could Leukemia achieve complete remission and that the 7-year event-free survival was 55.2 ± 7.8% in Japanese patients treated by the ANLL-91 protocol. Nonetheless, the results have still not been as good as in acute lymphoblastic leukemia (ALL). In childhood ALL, many studies have shown that clinical and biological features such as age, initial WBC, and immunological markers are associated with clinical outcomes. 2, 3, 21 In childhood AML, some prognostic factors have been analyzed. [22] [23] [24] [25] There are some reports of drug sensitivity testing with the MTT assay in childhood ALL, and drug sensitivity has been reported to provide prognostic information. [6] [7] [8] [9] [10] [11] Thus far, however, only a few studies have sought correlations between in vitro drug resistance and clinical outcome in childhood AML.
6,14-17 Sargent et al 12 indicated that the MTT assay was a suitable technique for routine application to testing the chemosensitivity of blast cells from patients with AML. Klumper et al 14 suggested that in vitro resistance to AraC correlated with chemotherapy failures in 29 cases of childhood initial AML. Kaspers et al 16 reported that in a group of 55 samples of newly diagnosed children with AML patients with more than 5% blasts in their BM at day 15 of remission induction chemotherapy had AML cells that were relatively more resistant to DNR, IDA, VP16 and AraC than those of the patients with less than 5% blasts. In adult AML, several studies Correlation between drug sensitivity and FAB classification. The drug sensitivity of FAB M2 and M5 cells is shown. The median LD70 of the M5 group (1.3 IU/ml; range: 0.010-10 IU/ml) to L-ASP was significantly lower than that of the M2 group (10 IU/ml; range: 0.010-10 IU/ml) (P = 0.0036). The median LCS of the M5 group (93.7%; range: 42.2-159%) to prednisolone was significantly higher than the M2 group (52.2%; range: 1.0-104%) (P Ͻ 0.0001). The concentration of prednisolone used to measure LCS was 0.16 g/ml to 100 g/ml. The LCS (%) for each sample was the mean percentage calculated from the LCSs of five concentrations.
have also reported good correlations between in vitro drug resistance and clinical response. Klumper et al 15 showed in adult AML that in vitro resistance to AraC, but not to DNR, was associated with an increased risk of relapse.
The effective drugs for remission induction in AML are the anthracyclines and AraC. 1, 2, 3, 26 The AML-BFM Study Group showed in the AML-BFM-83 trial 1 that the 8-day ADE (AraC, DNR, VP16) intensive induction therapy could reduce the relapse rate. Patients on CCG-2891 received a five-drug cycle of induction therapy (Dex, AraC, 6-TG, VP16 and DNR), with marked improvement of their event-free survival. 27 In addition to AraC and anthracyclines, VP16 is active in childhood AML. In our study, up to 70% of patients were treated by the ANLL-91 protocol. We found that drug resistance to AraC, VP16, L-PAM, L-ASP, ACR and Dex is significantly associated with short-term clinical outcome in childhood AML. From these results, we propose that in vitro drug resistance might be used as a new predictive factor for the early course of therapy and for risk-group stratification. Our retrospective study suggests that responses after administration of AraC and VP16 for induction therapy may predict whether patients can enter complete remission or not. A prospective study will be needed to clarify whether patients whose leukemic cells are resistant to AraC, L-PAM, VP16, L-ASP, ACR and Dex are really clinical non-responders. It is not surprising that the correlation between clinical response and in vitro drug resistance to L-PAM, L-ASP and Dex was not used clinically. Leukemic cells from non-responders were more resistant not only to the specific drugs that were used clinically, but also to other drugs that were not used clinically. These facts mean that leukemic cells of non-responders have already acquired multi-drug resistance or apoptosis resistance at initial onset. On the contrary, there were many cases that were sensitive to L-PAM, L-ASP and Dex among complete-responders. For these patients, we might use L-PAM, L-ASP and Dex clinically. We could not find a correlation between drug resistance and long-term clinical outcome, and concerning this, further analysis will be needed.
We analyzed the relationship between in vitro drug resistance and FAB type. We found that cells from FAB M1, M4 or M5 patients were significantly more sensitive to L-ASP than were M2 cells. Kaspers et al showed, that out of a group of 55 samples from children newly diagnosed with AML, M5 samples were more sensitive to vincristine and L-ASP than were the other samples. They also showed that the in vitro drug resistance profiles of AML M5 samples resembled those in ALL, except that the former are resistant to glucocorticoid. 16 Similarly, we found here that M5 cells were relatively sensitive to L-ASP, and were significantly more resistant to Pred and Dex than were M0, M1, M2, M4 and M7 cells.
Dü bbers et al 28 have reported that there is a lower asparagine synthetase activity in AML M5 cells, as well as in the Blineage ALL subgroups. In this way, it might explain the increased sensitivity of AML M5 samples to L-ASP. Thus, it might be possible to use L-ASP clinically for the treatment of M1, M4 and M5 patients, if their leukemic cells possessed lower levels of asparagine synthetase and were therefore more sensitive to L-ASP, as indicated by the MTT assay.
Zwaan et al 17 reported that the M5 subtype was significantly more sensitive, than M4 to most drugs frequently used in AML treatment and L-ASP. In our analysis, M5 was significantly more sensitive than M4 to VP16; in contrast, M4 was significantly more sensitive than M5 to ACR. Zwaan et al also reported that M5 was significantly more sensitive than M1/2 to VP16 and AraC. We have shown here that M5 was significantly more sensitive than M2 to VP16, but that M5 had the same sensitivity as M2 to AraC. There have been reports that VP16 has specific activity in acute monocytic leukemia. 29, 30 For AraC, we found that, when comparing median values, M0 was more resistant than any other subtype; however, the difference was only significant against M4 (P = 0.016). The relationship between the biological characteristics classified by the FAB subtypes and AraC metabolism requires further research.
Finally, we compared the in vitro drug resistance between M1 and M2 subtypes. Of interest, M1 cells were significantly more sensitive than M2 to many drugs such as VP16, L-ASP, THP, MIT and L-PAM. Zwaan et al 17 found no difference between the FAB M1 and M2 subtypes and analyzed M1 and M2 patients together as one category. However, as shown in our data, the difference in maturation of leukemic cells, even among cells of the same lineage, might alter their drug sensitivity. These results may help the choice of anti-cancer drugs according to subgroup-specific sensitivity.
In conclusion, in vitro drug resistance to AraC, L-PAM, VP16, L-ASP, ACR and Dex can predict short-term clinical outcome. The relationship between in vitro drug resistance and cell biological features of leukemias classified according to FAB subtypes has been clarified. Moreover, the MTT assay might be useful for predicting induction failure in childhood AML. To increase the cure rate in childhood AML, further studies are required to determine whether or not in vitro drug resistance can predict long-term clinical outcome. Nagoya), Dr Ryoji Hanada (Saitama Children's Medical Center, Iwatsuki), Dr Yasuo Horikoshi (Shizuoka Prefectural Children's Hospital, Shizuoka) and Dr Shuhei Yajima (Hamamatsu Medical Center, Hamamatsu) for providing the leukemia samples and for data collection.
